Ray Antonelli1, Kan Shao1, David J Thomas2, Reeder Sams3, John Cowden4. 1. ORISE Fellow, Hazardous Pollutant Assessment Group, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA. 2. Integrated Systems Toxicology Division, National Health and Environmental Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA. 3. Hazardous Pollutant Assessment Group, National Center for Environmental Assessment, Research Triangle Park Division, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA. 4. Hazardous Pollutant Assessment Group, National Center for Environmental Assessment, Research Triangle Park Division, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA. Electronic address: cowden.john@epa.gov.
Abstract
BACKGROUND: Oral exposure to inorganic arsenic (iAs) is associated with adverse health effects. Epidemiological studies suggest differences in susceptibility to these health effects, possibly due to genotypic variation. Genetic polymorphisms in iAs metabolism could lead to increased susceptibility by altering urinary iAs metabolite concentrations. OBJECTIVE: To examine the impact of genotypic polymorphisms on iAs metabolism. METHODS: We screened 360 publications from PubMed and Web of Science for data on urinary mono- and dimethylated arsenic (MMA and DMA) percentages and polymorphic genes encoding proteins that are hypothesized to play roles in arsenic metabolism. The genes we examined were arsenic (+3) methyltransferase (AS3MT), glutathione-s-transferase omega (GSTO), and purine nucleoside phosphorylase (PNP). Relevant data were pooled to determine which polymorphisms are associated across studies with changes in urinary metabolite concentration. RESULTS: In our review, AS3MT polymorphisms rs3740390, rs11191439, and rs11191453 were associated with statistically significant changes in percent urinary MMA. Studies of GSTO polymorphisms did not indicate statistically significant associations with methylation, and there are insufficient data on PNP polymorphisms to evaluate their impact on metabolism. DISCUSSION: Collectively, these data support the hypothesis that AS3MT polymorphisms alter in vivo metabolite concentrations. Preliminary evidence suggests that AS3MT genetic polymorphisms may impact disease susceptibility. GSTO polymorphisms were not associated with iAs-associated health outcomes. Additional data are needed to evaluate the association between PNP polymorphisms and iAs-associated health outcomes. Delineation of these relationships may inform iAs mode(s) of action and the approach for evaluating low-dose health effects for iAs. CONCLUSIONS: Genotype impacts urinary iAs metabolite concentrations and may be a potential mechanism for iAs-related disease susceptibility. Published by Elsevier Inc.
BACKGROUND: Oral exposure to inorganic arsenic (iAs) is associated with adverse health effects. Epidemiological studies suggest differences in susceptibility to these health effects, possibly due to genotypic variation. Genetic polymorphisms in iAs metabolism could lead to increased susceptibility by altering urinary iAs metabolite concentrations. OBJECTIVE: To examine the impact of genotypic polymorphisms on iAs metabolism. METHODS: We screened 360 publications from PubMed and Web of Science for data on urinary mono- and dimethylated arsenic (MMA and DMA) percentages and polymorphic genes encoding proteins that are hypothesized to play roles in arsenic metabolism. The genes we examined were arsenic (+3) methyltransferase (AS3MT), glutathione-s-transferase omega (GSTO), and purine nucleoside phosphorylase (PNP). Relevant data were pooled to determine which polymorphisms are associated across studies with changes in urinary metabolite concentration. RESULTS: In our review, AS3MT polymorphisms rs3740390, rs11191439, and rs11191453 were associated with statistically significant changes in percent urinary MMA. Studies of GSTO polymorphisms did not indicate statistically significant associations with methylation, and there are insufficient data on PNP polymorphisms to evaluate their impact on metabolism. DISCUSSION: Collectively, these data support the hypothesis that AS3MT polymorphisms alter in vivo metabolite concentrations. Preliminary evidence suggests that AS3MT genetic polymorphisms may impact disease susceptibility. GSTO polymorphisms were not associated with iAs-associated health outcomes. Additional data are needed to evaluate the association between PNP polymorphisms and iAs-associated health outcomes. Delineation of these relationships may inform iAs mode(s) of action and the approach for evaluating low-dose health effects for iAs. CONCLUSIONS: Genotype impacts urinary iAs metabolite concentrations and may be a potential mechanism for iAs-related disease susceptibility. Published by Elsevier Inc.
Authors: Rogelio Recio-Vega; Tania González-Cortes; Edgar Olivas-Calderón; R Clark Lantz; A Jay Gandolfi; Gladis Michel-Ramirez Journal: Environ Mol Mutagen Date: 2016-06-21 Impact factor: 3.216
Authors: Christelle Douillet; Madelyn C Huang; R Jesse Saunders; Ellen N Dover; Chongben Zhang; Miroslav Stýblo Journal: Arch Toxicol Date: 2016-11-15 Impact factor: 5.153
Authors: Ming Li; Andrew E Jaffe; Richard E Straub; Ran Tao; Joo Heon Shin; Yanhong Wang; Qiang Chen; Chao Li; Yankai Jia; Kazutaka Ohi; Brady J Maher; Nicholas J Brandon; Alan Cross; Joshua G Chenoweth; Daniel J Hoeppner; Huijun Wei; Thomas M Hyde; Ronald McKay; Joel E Kleinman; Daniel R Weinberger Journal: Nat Med Date: 2016-05-09 Impact factor: 53.440
Authors: Antonio J Signes-Pastor; Jesús Vioque; Eva M Navarrete-Muñoz; Manus Carey; Miguel García-Villarino; Ana Fernández-Somoano; Adonina Tardón; Loreto Santa-Marina; Amaia Irizar; Maribel Casas; Mònica Guxens; Sabrina Llop; Raquel Soler-Blasco; Manoli García-de-la-Hera; Margaret R Karagas; Andrew A Meharg Journal: Environ Res Date: 2019-04-29 Impact factor: 6.498